Degarelix for treating advanced hormone-dependent prostate cancer

  • Technology appraisal guidance
  • TA404
  • Published: 
Download guidance (PDF)

3 Evidence

The appraisal committee (section 7) considered evidence submitted by Ferring Pharmaceuticals and reviews of these submissions by the evidence review group (ERG) and the Decision Support Unit (DSU). See the committee papers for full details of the evidence.